Viracta Therapeutics (VIRX) News Today → Executive Order To Wipe Out Your Bank Accounts (From Oasis Gold) (Ad) Free VIRX Stock Alerts $0.62 -0.02 (-2.98%) (As of 06/7/2024 08:52 PM ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 23, 2024 | markets.businessinsider.comOppenheimer Keeps Their Buy Rating on Viracta Therapeutics (VIRX)May 18, 2024 | finanznachrichten.deViracta Therapeutics, Inc.: Viracta Therapeutics Announces New Employment Inducement GrantsMay 17, 2024 | globenewswire.comViracta Therapeutics Announces New Employment Inducement GrantsMay 14, 2024 | globenewswire.comViracta Therapeutics Appoints Michael Faerm as Chief Financial OfficerMay 10, 2024 | markets.businessinsider.comRBC Capital Keeps Their Buy Rating on Viracta Therapeutics (VIRX)May 10, 2024 | investorplace.comVIRX Stock Earnings: Viracta Therapeutics Beats EPS for Q1 2024May 9, 2024 | globenewswire.comViracta Therapeutics Reports First Quarter 2024 Financial Results and Provides Business UpdateMay 7, 2024 | globenewswire.comViracta Therapeutics to Present at the RBC Capital Markets Global Healthcare ConferenceApril 23, 2024 | msn.comDay One wins FDA nod for brain cancer therapy, OjemdaApril 18, 2024 | markets.businessinsider.comPromising Clinical Trial Results Reinforce Buy Rating for Viracta TherapeuticsApril 17, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Viracta Therapeutics (VIRX) and UnitedHealth (UNH)April 16, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Icecure Medical (ICCM), Viracta Therapeutics (VIRX) and Bioxcel Therapeutics (BTAI)April 15, 2024 | msn.comWhy Is Small-Cap Cancer Drug Developer Viracta Therapeutics Stock Trading Lower On Monday?April 15, 2024 | globenewswire.comViracta Therapeutics Announces Positive Topline Nana-val Results from Stage 1 of the NAVAL-1 Trial in Patients with Relapsed or Refractory Epstein-Barr Virus-Positive (EBV+) Peripheral T-Cell LymphomaApril 1, 2024 | globenewswire.comViracta Therapeutics to Present Topline Nana-val Results from Stage 1 of the NAVAL-1 Trial at the 2024 Annual Congress of The Hematology Society of TaiwanMarch 22, 2024 | investing.comViracta Therapeutics CFO and COO Dan Chevallard resignsMarch 12, 2024 | markets.businessinsider.comBuy Rating for Viracta Therapeutics Backed by Upcoming Catalysts and Solid FinancialsMarch 8, 2024 | msn.comVIRX Stock Earnings: Viracta Therapeutics Misses EPS for Q4 2023March 7, 2024 | globenewswire.comViracta Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business UpdateFebruary 29, 2024 | globenewswire.comViracta Therapeutics Announces Completion of Second-Stage Enrollment into the Peripheral T-Cell Lymphoma Cohort of the NAVAL-1 TrialFebruary 17, 2024 | finance.yahoo.comVIRX Mar 2024 2.500 callFebruary 6, 2024 | finance.yahoo.comViracta Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences ConferenceJanuary 4, 2024 | finance.yahoo.comViracta Therapeutics Provides Clinical Update and Outlook for 2024December 22, 2023 | benzinga.comViracta Therapeutics Stock (NASDAQ:VIRX) Dividends: History, Yield and DatesDecember 12, 2023 | msn.comViracta gets orphan drug status for Nana-val for EBV tumorsDecember 12, 2023 | finance.yahoo.comViracta Therapeutics Announces Orphan Drug Designation Granted by the U.S. FDA to Nana-val for the Treatment of Nasopharyngeal CarcinomaDecember 4, 2023 | finance.yahoo.comViracta Therapeutics Announces Interim Data from Phase 1b/2 Clinical Trial of Nana-val in Patients with Epstein-Barr Virus-Positive Solid Tumors that Show Confirmed Tumor Responses at Higher Dose LevelsNovember 18, 2023 | morningstar.comViracta Therapeutics Inc VIRXNovember 9, 2023 | benzinga.comViracta Therapeutics: Q3 Earnings InsightsNovember 9, 2023 | finance.yahoo.comViracta Therapeutics Inc (VIRX) Reports Q3 2023 Financial Results Amid Clinical AdvancesNovember 9, 2023 | finance.yahoo.comViracta Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business UpdateOctober 5, 2023 | markets.businessinsider.comPromising Developments in Viracta Therapeutics Research and Trials Bolster Buy RatingOctober 4, 2023 | finance.yahoo.comViracta Therapeutics to Host R&D Day Highlighting Nana-val in Epstein-Barr Virus (EBV)-Associated CancersSeptember 5, 2023 | finance.yahoo.comViracta Therapeutics to Host R&D Day on October 4, 2023August 19, 2023 | finanznachrichten.deViracta Therapeutics, Inc.: Viracta Therapeutics Announces New Employment Inducement GrantAugust 15, 2023 | msn.comRBC Capital Reiterates Viracta Therapeutics (VIRX) Outperform RecommendationAugust 15, 2023 | markets.businessinsider.comExpert Ratings for Viracta TherapeuticsAugust 15, 2023 | markets.businessinsider.comRBC Capital Sticks to Their Buy Rating for Viracta Therapeutics (VIRX)August 15, 2023 | markets.businessinsider.comViracta Therapeutics (VIRX) Receives a Buy from H.C. WainwrightAugust 8, 2023 | finance.yahoo.comViracta Therapeutics Announces Publication in Blood Advances Demonstrating Promising and Durable Signal of Nana-val Efficacy in Patients with Relapsed or Refractory (R/R) Epstein-Barr Virus-Positive (EBV+) LymphomaAugust 7, 2023 | seekingalpha.comViracta Therapeutics gets new chief medical officerAugust 7, 2023 | markets.businessinsider.comViracta Therapeutics Names Darrel Cohen Chief Medical OfficerAugust 7, 2023 | finance.yahoo.comViracta Therapeutics Appoints Darrel P. Cohen, M.D., Ph.D. as Chief Medical OfficerAugust 3, 2023 | msn.comViracta Therapeutics (VIRX) Price Target Decreased by 28.57% to 10.20July 19, 2023 | fool.comViracta Therapeutics (NASDAQ: VIRX)July 6, 2023 | msn.comViracta Therapeutics (VIRX) Price Target Decreased by 5.41% to 14.28July 5, 2023 | msn.comHC Wainwright & Co. Reiterates Viracta Therapeutics (VIRX) Buy RecommendationJune 28, 2023 | finance.yahoo.comViracta Therapeutics Says Pivotal Cancer Trial Achieves Efficacy Threshold For Expansion Into Next StageJune 28, 2023 | finance.yahoo.comViracta Therapeutics’ Pivotal NAVAL-1 Trial Achieves Efficacy Threshold for Expansion in Relapsed or Refractory EBV-positive Peripheral T-Cell Lymphoma (R/R EBV+ PTCL)May 11, 2023 | msn.comHC Wainwright & Co. Maintains Viracta Therapeutics (VIRX) Buy Recommendation Get Viracta Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for VIRX and its competitors with MarketBeat's FREE daily newsletter. Email Address Trump convicted... now what? (Ad)Unexpected Twist to Trump's Trial Most folks sense there's more to the Trump trial than meets the eye. But while the Left celebrates his conviction... and the Right rallies around him... the average American is not prepared for what happens next. Which is why it's so important to access this presentation while it's still available online. VIRX Media Mentions By Week VIRX Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. VIRX News Sentiment▼0.000.76▲Average Medical News Sentiment VIRX News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. VIRX Articles This Week▼01▲VIRX Articles Average Week Get Viracta Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for VIRX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: ASRT News CNTB News HILS News RLMD News PMVP News ORMP News DERM News CMRX News ASMB News YS News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:VIRX) was last updated on 6/10/2024 by MarketBeat.com Staff From Our PartnersAlert: Your Bank is Dying – Act Now or Lose Everything!Get your free information kit NOW, before it’s too late. Inside you’ll get the 3 secret strategies you can put...Priority Gold | SponsoredTrump convicted... now what?Unexpected Twist to Trump's Trial Most folks sense there's more to the Trump trial than meets the eye. B...Stansberry Research | SponsoredIt's time to ween off Chinese lithium!As the lithium rush continues, this small-cap NASDAQ-traded company may be one of the brightest and most promi...Smallcaps Daily | SponsoredTop 5 Tech Stocks to Buy for 2024The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...Daily Market Alerts | SponsoredTop 5 AI Stocks to Buy for 2024The electric vehicle boom is accelerating – and fast.Market Moving Trends | SponsoredNo Strings Attached: Get 30 Days of Hedgeye’s Top Stock Picks for FreeOptimize your stock investing strategy with Hedgeye's Investing Ideas, where rigorous fundamental stock analys...Hedgeye | SponsoredHurry! Buy this stock before the Robinhood traders do!Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | SponsoredAI's Next Magnificent SevenThe Original Magnificent Seven Produced 16,894% Average Returns Over 20 Years.The Oxford Club | Sponsored